Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer
July 31st 2023Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab/chemotherapy as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.
FDA Issues CRL for Denileukin Diftitox in R/R Cutaneous T-Cell Lymphoma
July 31st 2023The regulatory agency requests enhanced product testing and additional controls in their market application review of denileukin diftitox for the treatment of those with relapsed/refractory cutaneous T-cell lymphoma.
FDA Approves Ready-to-Dilute Cyclophosphamide Injection NDA in Blood Cancers
July 10th 2023Patients with select hematologic cancers, including lymphoma and multiple myeloma, appear to benefit from a ready-to-dilute formation of intravenous cyclophosphamide, the new drug application for which was approved by the FDA.